![]() |
市場調查報告書
商品編碼
2179078
人工智慧驅動的精準腫瘤平台市場預測至2034年——全球平台組件、人工智慧技術、數據模式、臨床應用、最終用戶和地區分析AI-Driven Precision Oncology Platforms Market Forecasts to 2034 - Global Analysis By Platform Component (Software and Services), AI Technology, Data Modality, Clinical Application, End User and By Geography |
||||||
根據 Stratistics MRC 的數據,全球人工智慧驅動的精準腫瘤學平台市場在 2026 年估計為 32 億美元,預計到 2034 年將達到 134 億美元,預測期內複合年成長率為 19.6%。
人工智慧驅動的精準腫瘤學平台利用機器學習、深度學習、自然語言處理和多模態分析技術,分析分子、臨床和影像數據,從而實現個人化癌症治療。癌症發生率的上升、基因組分析的日益普及以及對個人化治療決策需求的不斷成長,正在推動市場發展。生成式人工智慧、分子診斷和預測分析技術的進步,正在提升臨床決策支援能力。對精準醫療、腫瘤學研究和數位醫療基礎設施的持續投入,正在為醫院、癌症中心和製藥公司創造商機。
對個人化癌症治療和人工智慧驅動的臨床決策支援的需求日益成長。
對個人化癌症治療和人工智慧驅動的臨床決策支援日益成長的需求,正在推動精準腫瘤學平台的普及應用。醫療服務提供者正擴大利用基因組分析、分子診斷和人工智慧來識別可操作的生物標記,並輔助治療方案的選擇。這些平台能夠幫助臨床醫生解讀複雜的分子訊息,並評估標靶治療方案。癌症發生率的上升、精準醫療計畫的擴展以及基因組數據可用性的提高,都在推動精準腫瘤學平台的普及應用。機器學習和臨床數據整合技術的進步,也進一步促進了市場的發展。
實施成本高昂,且臨床數據整合面臨許多挑戰
高昂的實施成本和臨床數據整合的挑戰阻礙了人工智慧驅動的精準腫瘤學平台的普及應用。先進的解決方案需要複雜的運算基礎設施、安全的資料環境、專業人員以及與現有醫療資訊系統的整合。基因組資料格式、電子健康記錄和診斷流程的差異增加了互通性的難度。特定人工智慧服務的保險報銷限制以及臨床有效性的不確定性也構成了進一步的障礙。小規模的醫療機構在實施綜合平台時可能會面臨財務和技術方面的挑戰。
多模態人工智慧和整合精準腫瘤學應用的擴展
多模態人工智慧和精準腫瘤學應用的擴展帶來了巨大的成長機會。先進的平台整合了基因組圖譜、數位病理學、醫學影像和臨床記錄,從而產生全面的患者資訊。生成式人工智慧和基礎模型為改善分子層面的解讀、臨床試驗配對和治療研究提供了契機。製藥公司正日益利用人工智慧驅動的分析技術進行生物標記發現和標靶治療開發。對整合醫療數據平台和個人化腫瘤學的持續投入正在推動技術創新。
人們擔憂演算法的可靠性以及日益增加的患者資料安全風險。
對演算法可靠性的擔憂以及患者資料安全風險的增加,為人工智慧驅動的精準腫瘤學平台帶來了重大挑戰。不準確的分子分析、偏差的訓練資料集或檢驗不足的預測都可能影響臨床決策。處理敏感的基因組和患者資訊引發了網路安全和保密方面的擔憂。日益嚴格的監管審查和對可解釋人工智慧(XAI)不斷成長的要求推高了開發成本。與現有臨床決策支援系統和傳統分子分析流程的競爭,進一步加劇了商業化和應用推廣的難度。
新冠疫情加速了醫療數位化進程,並提升了人們對遠距臨床協作和人工智慧診斷技術的興趣。在常規醫療服務中斷期間,腫瘤相關機構探索利用數位平台來支持分子腫瘤委員會、臨床數據解讀和治療方案。然而,癌症診斷的延遲、臨床試驗的中斷以及醫療預算的限制影響了這些技術的應用。隨後,對數位醫療基礎設施、精準醫療和人工智慧腫瘤工作流程的投資持續成長,推動了市場發展。
在預測期內,軟體領域預計將佔據最大的市場佔有率。
人工智慧驅動的分子層次解讀、臨床決策支援和整合腫瘤分析平台的日益普及,預計將推動軟體領域在預測期內佔據最大的市場佔有率。軟體解決方案整合基因組數據、電子健康記錄和診斷訊息,以支援個人化治療決策。精準腫瘤學計畫、雲端醫療平台和自動化生物標記分析的投資增加,正在推動其應用。機器學習、工作流程整合和可擴展臨床分析的進步,進一步促進了該領域的成長。
預計在預測期內,多模態人工智慧和基礎模型細分市場將呈現最高的複合年成長率。
在預測期內,由於對整合解讀各種腫瘤資料集的需求日益成長,多模態人工智慧和基礎建模領域預計將呈現最高的成長率。這些技術結合了基因組資訊、病理影像、放射學觀察和臨床記錄,以支持全面的癌症評估。基礎模型、生成式人工智慧和運算基礎設施的進步正在增強分析能力。對個人化治療預測、生物標記發現和腫瘤學研究投入的增加預計將加速這些技術的應用。
在預測期內,北美預計將佔據最大市場佔有率,這主要得益於其先進的醫療基礎設施、對人工智慧的大量投資以及廣泛的精準腫瘤學活動。美國正透過生物技術公司、癌症研究中心和醫療機構推動區域發展,這些機構正在採用人工智慧驅動的分子分析平台。基因組檢測的日益普及、完善的臨床試驗網路以及對個人化醫療日益成長的需求,都在推動這些技術的應用。技術創新以及診斷開發公司與醫療服務提供者之間的夥伴關係,正在加強商業化進程。
在預測期內,亞太地區預計將呈現最高的複合年成長率,這主要得益於醫療基礎設施的不斷改進、癌症發病率的上升以及對人工智慧技術投資的增加。中國、日本、印度、韓國和澳洲正在推動精準腫瘤學計畫和基因組檢測能力。分子診斷技術的普及、數位醫療措施的拓展以及臨床研究的不斷深入,正在加速這些技術的應用。政府對科技的投資以及醫療機構與生技公司之間的合作,也為該地區的成長提供了支持。
According to Stratistics MRC, the Global AI-Driven Precision Oncology Platforms Market is estimated at $3.2 billion in 2026 and is expected to reach $13.4 billion by 2034, growing at a CAGR of 19.6% during the forecast period. AI-Driven Precision Oncology Platforms utilize machine learning, deep learning, natural language processing, and multimodal analytics to interpret molecular, clinical, and imaging data for personalized cancer management. Increasing cancer prevalence, growing adoption of genomic profiling, and demand for individualized treatment decisions are driving market growth. Technological advancements in generative AI, molecular diagnostics, and predictive analytics are improving clinical decision support. Expanding investment in precision medicine, oncology research, and digital healthcare infrastructure creates opportunities across hospitals, cancer centers, and pharmaceutical companies.
Increasing demand for personalized cancer treatment and AI-enabled clinical decision support
Increasing demand for personalized cancer treatment and AI-enabled clinical decision support is driving adoption of precision oncology platforms. Healthcare providers increasingly utilize genomic profiling, molecular diagnostics, and artificial intelligence to identify actionable biomarkers and support treatment selection. These platforms help clinicians interpret complex molecular information and evaluate targeted therapy options. Growing cancer prevalence, expanding precision medicine programs, and increasing availability of genomic data encourage adoption. Advances in machine learning and clinical data integration further strengthen market development.
High implementation costs and challenges in clinical data integration
High implementation costs and challenges in clinical data integration restrain adoption of AI-driven precision oncology platforms. Advanced solutions require sophisticated computational infrastructure, secure data environments, specialized personnel, and integration with existing hospital information systems. Differences in genomic data formats, electronic health records, and diagnostic workflows complicate interoperability. Limited reimbursement for certain AI-enabled services and uncertainty regarding clinical validation create additional barriers. Smaller healthcare organizations may face financial and technical challenges when implementing comprehensive platforms.
Expansion of multimodal AI and integrated precision oncology applications
Expansion of multimodal AI and integrated precision oncology applications presents significant growth opportunities. Advanced platforms combine genomic profiles, digital pathology, medical imaging, and clinical records to generate comprehensive patient insights. Generative AI and foundation models offer opportunities to improve molecular interpretation, clinical trial matching, and treatment research. Pharmaceutical companies increasingly utilize AI-driven analytics for biomarker discovery and targeted therapy development. Growing investment in integrated healthcare data platforms and personalized oncology supports technological innovation.
Algorithm reliability concerns and increasing patient data security risks
Algorithm reliability concerns and increasing patient data security risks pose significant challenges to AI-driven precision oncology platforms. Inaccurate molecular interpretations, biased training datasets, or poorly validated predictions may influence clinical decisions. Processing sensitive genomic and patient information creates cybersecurity and confidentiality concerns. Increasing regulatory scrutiny and requirements for explainable artificial intelligence raise development costs. Competition from established clinical decision support systems and conventional molecular interpretation workflows further challenges commercialization and widespread adoption.
The COVID-19 pandemic accelerated healthcare digitalization and increased interest in remote clinical collaboration and AI-enabled diagnostic technologies. Oncology organizations explored digital platforms to support molecular tumor boards, clinical data interpretation, and treatment planning during disruptions to routine services. However, delayed cancer diagnoses, interrupted clinical trials, and constrained healthcare budgets affected implementation activities. Subsequent investment in digital healthcare infrastructure, precision medicine, and AI-supported oncology workflows continues to encourage market development.
The software segment is expected to be the largest during the forecast period
The software segment is expected to account for the largest market share during the forecast period due to increasing adoption of AI-enabled molecular interpretation, clinical decision support, and integrated oncology analytics platforms. Software solutions combine genomic data, electronic health records, and diagnostic information to support personalized treatment decisions. Growing investment in precision oncology programs, cloud-based healthcare platforms, and automated biomarker analysis encourages adoption. Advances in machine learning, workflow integration, and scalable clinical analytics strengthen segment growth.
The multimodal AI & foundation models segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the multimodal AI & foundation models segment is predicted to witness the highest growth rate due to increasing demand for integrated interpretation of diverse oncology datasets. These technologies combine genomic information, pathology images, radiology findings, and clinical records to support comprehensive cancer assessment. Advances in foundation models, generative AI, and computational infrastructure improve analytical capabilities. Growing investment in personalized treatment prediction, biomarker discovery, and oncology research is expected to accelerate adoption.
During the forecast period, North America is expected to hold the largest share due to advanced healthcare infrastructure, substantial investment in artificial intelligence, and extensive precision oncology activities. The United States leads regional development through biotechnology companies, cancer research centers, and healthcare organizations deploying AI-enabled molecular interpretation platforms. Increasing adoption of genomic testing, established clinical trial networks, and growing demand for personalized treatment encourage utilization. Technological innovation and partnerships between diagnostic developers and healthcare providers strengthen commercialization.
Over the forecast period, Asia Pacific is anticipated to exhibit the highest CAGR, supported by expanding healthcare infrastructure, increasing cancer prevalence, and growing investment in artificial intelligence technologies. China, Japan, India, South Korea, and Australia are advancing precision oncology programs and genomic testing capabilities. Improving access to molecular diagnostics, expanding digital healthcare initiatives, and increasing clinical research encourage adoption. Government technology investments and collaborations between healthcare institutions and biotechnology companies support regional growth.
Key players in the market
Some of the key players in the AI-Driven Precision Oncology Platforms Market include Tempus AI, Inc., Caris Life Sciences, Inc., SOPHiA GENETICS SA, Foundation Medicine, Inc., Guardant Health, Inc., BostonGene Corporation, GenomOncology LLC, Perthera, Inc., Owkin, Inc., PathAI, Inc., Artera, Inc., QIAGEN N.V., Fabric Genomics, Inc., Flatiron Health, Inc., Syapse, Inc., Roche Holding AG, Illumina, Inc., and Microsoft Corporation.
In October 2026, Tempus AI, Inc. announced an expanded multi-year strategic collaboration with Bristol Myers Squibb to provide multimodal oncology data and access to its AI-powered Lens platform. The agreement supports oncology drug discovery, clinical research, and the development of advanced AI models for identifying therapeutic targets and improving precision oncology research.
In August 2026, Caris Life Sciences, Inc. announced the publication of research in npj Precision Oncology demonstrating an AI-driven approach to predicting first-line treatment benefit in pancreatic cancer. The study evaluated Caris AI Insights molecular signatures to support personalized therapy selection and improve clinical decision-making.
In June 2026, SOPHiA GENETICS SA announced a memorandum of understanding with Memorial Sloan Kettering Cancer Center to explore establishing a precision medicine joint venture. The collaboration aims to combine clinical diagnostic expertise with the SOPHiA DDM AI platform to develop and deploy advanced precision oncology solutions.
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.